anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: This narrative review aims to provide a clinical perspective on the potential role of co-crystal of tramadol-celecoxib (CTC) in the management of acute moderate-to-severe pain by synthesizing the available preclinical and clinical data, with emphasis on phase 3 trials.
METHODS: A non-systematic literature review was performed using a targeted PubMed search for articles published between January 1, 2000, and May 2, 2023; all publication types were permitted, and selected articles were limited to those published in English. Search results were manually reviewed to identify references based on their preclinical and clinical relevance to CTC and management of acute moderate-to-severe pain.
RESULTS: The crystalline structure of CTC alters the physicochemical properties of tramadol and celecoxib, modifying their pharmacokinetics. If taken in a free combination, tramadol reduces absorption of celecoxib. Conversely, administration of CTC slows tramadol absorption and lowers its maximum plasma concentration, while increasing celecoxib plasma concentration through its enhanced release. In clinical studies across models of acute moderate-to-severe pain, CTC demonstrated an early onset of analgesia, with improved efficacy and lower rescue medication use, compared with either agent alone. CTC's safety profile was in line with that expected for the individual components; no additive effects were observed. CTC exhibited tramadol-sparing effects, with efficacy seen at lower daily/cumulative opioid doses vs. tramadol alone.
CONCLUSIONS: Results from phase 3 trials suggest that the modified physicochemical properties of tramadol and celecoxib in CTC translate into an improved clinical benefit-risk profile, including fewer opioid-related adverse effects due to lower overall opioid dosing.
Subjects will receive eight weeks of no hyperbaric treatment while they continue any pre-study maintenance medication and/or pre-study counseling. Subjects will be retested and the control group will be crossed over to receive the identical 40 HBOTs of the HBOT group.
Articles for treating the skin having high plasticity and low ware rate are described. Articles herein described are proper for treating the skin by rubbing them onto the skin, for example, in the form of a soap bar presenting increased plasticity and low rate of wear. The preferred embodiment is an article that has one or multiple projections arising from at least one surface of a first body are described. The first body and the projections are a thermoplastic mass that includes a surfactant suitable for cleansing skin and a plasticizing agent. The articles are especially suited for projection bars used to be applied onto the skin for either cleansing or massaging or both at the same time. Robust and economical projection bars are described that can be efficiently manufactured by the careful selection of the plasticity, wear rate and rheological properties of the masses of the first body and projections.
Use of natural or synthetic, opt. modified ammonium or alkali humates (with a md. wt. of up to 50,000D), whose aq. solns. show no Tyndall effect and do not fluoroesce, for prepn. of medicaments for promotion of resorption of hydroxyapatite-based implants, is new. Agents contg. the humates are also claimed. The dotted line represents an opt. second bond; R1, R3, R4 = H or OH; R2 = CO or CH2; R5, R6 = H, OH or OMe; Provided that R5, R6 and R4 are not all H. USE/ADVANTAGE - The agents allow promotion of the resorption of hydroxyapatite implants without influencing the osteoconductivity of the implants. These implants have better pressure stability than tricalcium phosphate implants (which are often used due to their good resorbability properties). The implants are useful in bone transplant operations.
In certain aspects, a computer-implemented method is includes receiving a request from a user device comprising a user profile comprising medical and social information of a user associated with the user device. The method includes adding, responsive to receiving the request, the user device to a queue. The method includes selecting a personal care partner device to connect with the user device based on care parameters. The method includes displaying, on the personal care partner device, selected information of the medical and social information responsive to the personal care partner device being selected. The method includes connecting, responsive to the personal care partner device accepting the request, the user device to the personal care partner device. The method includes generating a log of monitored information received from the personal care partner device and the user device, and includes updating the user profile with the log of monitored information.
The complex improves the stability and increases the potential of interferon (IFN). The application of the interferon in the form of a complex with an IFN binding chain of the human interferon alpha/beta receptor (INFAR) prolongs the in vivo effect of Type I interferon The complex of IFN and IFNAR is effected by a covalent link or a peptide, or by non-covalent link. When bound by a peptide link in the form of fusion protein, IFN can be separate from IFNAR by means of a peptide binding sector. Such a fusion protein can be produced by rDNA technology. Storing IFN in the form of such a complex enables its storage under milder conditions for a longer period. 33 claims, 17 figures
The invention relates to a Chinese traditional medicine preparation for curing cattle fever. The cattle fever is an urgent general illness caused by virus, and is usually sudden and serious fever, with infectivity. The medicament of the invention has main raw material medicines of china root of 9 to 3 and silkworm droppings of 6 to 15 by weight proportion and is made by decoction in full water. The medicament of the invention has simple form of the raw raw material medicines, enough medicine sources and can resist virus, release the discomfort of alimentary canal and respiratory tract, dispel the symptom of arthrosis pain with inner and outer treatment. The invention has obvious and rapid curative effect when applied in clinic, with an effectiveness ratio of 100 percent and a cure rate above 95 percent. The raw material medicines of the china root and the silkworm droppings have a wide safety range, without medicine toxic reaction or other side effects. Besides, the invention has a treatment charge only one tenth of that of similar western medicines, thus having a low treatment cost.
Prostate cancer (PCa) is the second cause of cancer death among men worldwide. Several processes are involved in the development and progression of PCa such as angiogenesis, inflammation and oxidative stress. The present study investigated the effect of short- or long-term Tempol treatment at different stages of prostate adenocarcinoma progression, focusing on angiogenic, proliferative, and stromal remodeling processes in TRAMP mice. The dorsolateral lobe of the prostate of TRAMP mice were evaluated at two different stages of PCa progression; early and late stages. Early stage was again divided into, short- or long-term. 50 mg/kg Tempol dose was administered orally. The results demonstrated that Tempol mitigated the prostate histopathological lesion progressions in the TRAMP mice in all treated groups. However, Tempol increased molecules involved in the angiogenic process such as CD31 and VEGFR2 relative frequencies, particularly in long-term treatment. In addition, Tempol upregulated molecule levels involved in angiogenesis and stromal remodeling process VEGF, TGF-β1, VE-cadherin and vimentin, particularly, in T8-16 group. Thus, it was concluded that Tempol treatment delayed prostatic lesion progression in the dorsolateral lobe of the TRAMP mice. However, Tempol also led to pro-angiogenic effects and glandular stromal microenvironment imbalance, especially, in the long-term treatment.
The shoulder joint complex in the overhead athlete is organized to effectively transfer the proximally generated forces distally into the arm. The organization also protects the joints and anatomic structures against the repetitive high velocities, large ranges of motions, and compressive, shear, translational, and distraction loads in the overhead motion while placing the hand in the "launch window." Coupling of the movements of the scapula, clavicle, and humerus results in scapulohumeral rhythm (SHR). Effective SHR requires the clavicle and scapula-and, at times, the mechanically linked claviscapular segment-to move the arm into the task-specific position and motion and requires the humerus to move through the ranges of motion to achieve the specific task in the throwing motion. Alterations in SHR can negatively affect effective shoulder joint complex function in the overhead throwing motion and increase injury risk. There are 4 phases of clavicular, scapular, and claviscapular motion that are coupled with arm motion in SHR. The first 3 phases occur in arm elevation motions from 0°-90° and result in the claviscapula and humerus being placed in task-specific positions. The fourth phase is coupling of claviscapular motion with humeral motion to maintain ball-and-socket kinematics throughout the throwing motion. Alterations in this composite motion are termed "scapular dyskinesis." The dyskinesis is considered an impairment of the efficient mobility of the claviscapular segment of the shoulder complex. The most prevalent problem with scapular dyskinesis is the association of scapular protraction and consequent glenoid antetilt with alterations in humeral rotation and posterior humeral head translation to produce shoulder joint internal impingement. Task effectiveness in overhead throwing is also based on and determined by humeral range of motion, precision of humeral motion, and velocity of humeral motion, as well as humeral and arm position in 3-dimensional space. This activity requires maximum ball-and-socket kinematics to create the highest amount of concavity-compression that creates stability for the joint. There are bony and soft-tissue contributions to this stability. Injuries to the glenoid labrum are among the most common deficits that alter concavity-compression. Clinical evaluation of the shoulder joint complex in the injured throwing athlete should be comprehensive and systematic, following an evaluation pathway for proximal and distal causative factors and including observation of humeral motion. This type of evaluation can result in intervention protocols that address the pathoanatomic, pathophysiological, and pathomechanical deficits identified.
Efforts have been made in the past to improve the wellbeing of a person. Various methods involve use of virtual pet character which can interact with the person. But these methods are mainly for entertainment purpose, people get bored quickly. Moreover, the present application doesn't take into the input of the present state of user. A method and system for improving wellbeing of person using a digital character such as virtual pet has been provided. The system maintains a wellbeing index for both the user and digital character. A set of activities are provided which is performed by the digital character and the user. Further, a response of the user is also captured depending on the current wellbeing index using a set of questionnaire. And a second set of activities are recommended based on the response to further improve the wellbeing index of the person.
PURPOSE:To obtain a remedy or prophylactic for ischemic heart diseases which contains + or --4-(4-chlorobenzyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1(2h)-phtha lazinone or its salt as an active ingredient. CONSTITUTION:The objective remedy or prophylactic is obtained by using the compound of the formula or its salt as an active ingredient and customary carriers for medicament preparation and making pharmaceutical preparations in a usual manner. The compound can be made into injection solution, suppository, external preparation, instillation solution and other parenteral preparations and powder, capsules, syrup and other oral preparations. The composition is preferably served in the form suitable for enteric absorption. The dose is 0.01-200mg/adult/day and given in portions. The compound of the formula inhibits leukocytes from infiltrating into the ischemic parts in cardiac muscles to suppress the necrosis of the ischemic cardiac muscles.
This is a Phase lla open-label (all people involved know the identity of the treatment), randomized (study drug assigned by chance), controlled (the patients of the control group continue the failing regimen), dose-finding study to determine the antiviral activity, safety and tolerability of a 14-day treatment with TMC114 (a protease inhibitor) for treatment of human immunodeficiency virus type 1 (HIV-1) positive patients who are considered resistant to (failing to improve on) 2 or more protease inhibitors (PIs). Sixty HIV-1 positive patients, who are resistant to multiple PIs as confirmed by specialized testing (virtual phenotyping) and who are currently failing to improve on a treatment regimen that contains a PI, will be randomly assigned to one of 5 treatment groups. Those randomized to the control group will continue their current therapy (consisting of PIs and Nucleoside Reverse Transcriptase Inhibitor(s) (NRTIs)). Those randomized to the TMC114 treatment groups will receive the study drug as a substitute for all the PIs in the current failing treatment regimen at the following dose levels: 400 or 800 mg twice a day, or 800 or 1200 mg three times a day for 13 days followed by a single dose on day 14. The dose of the NRTIs (NRTIs are drugs that suppress replication of retroviruses) will remain unchanged until the end of the treatment period. The trial will involve a screening period of maximum three weeks, a 7-day run-in period (the period of time before study start when no treatment is given), a 14-day treatment period, followed by a 6- week follow-up period. The maximal trial duration will thus be twelve weeks. Primary objective is to determine the antiviral activity of TMC114 as well as the pharmacokinetics (how the drug is absorbed in the body, distributed within the body and how it is removed from the body over time) and pharmacodynamics (the study of the action of effects a drug has on the body) will also be assessed over the 2 week period.Safety will be followed at regular intervals during treatment and follow-up period. Safety assessments consist of regular lab assessments, ECG recording, vital signs, physical examination, body weight and Body Mass Index. Observation of and interview for adverse events will be done daily during the first week of treatment, every second day during the 2nd week of treatment, and at week 1, 3 and 6 of the follow-up period. In addition an Independent Data Monitoring Committee will evaluate the study data at regular intervals. Patients will be randomly assigned to one of 5 treatment groups: 400 or 800 mg twice a day for 13 days followed by a single dose on day 14, or 800 or 1200 mg three times a day for 13 days followed by a single dose on day 14. Patients randomized to the control group will continue their current therapy consisting of protease inhibitors (PIs) and Nucleoside Reverse Transcriptase Inhibitors (NRTIs).
The invention relates to the use of low-molecular glycosidic compounds with terminal D-galactose and L-fucose in the treatment of intoxications with ricin. The identified compounds form a lectin bond with the B chain of the ricin and thereby prevent further endocytosis of the toxins. The compounds should be ingested as early as possible after incorporation of the toxin and can also be used preventively. The groups bonded to the D-galactose and L-fucose can be other saccharides (e.g. fructose), polyalcohols (e.g. sorbitol), diacyl-glycerides or flavonoids (e.g. quercetin). 
     Galactose-heteropolysaccharide hydrolysates such as guar gum flour can also be used. The identified compounds can be used for oral, pulmonary and systemic intoxications. They should be used in corresponding pharmaceutical forms of administration. The compounds are dosed in molar excess.
Participants will receive the M3F program. The M3F program is divided into three phases, being the first two of weight loss and the third phase of weight maintenance.
Currently, there is little information about which is the safest modality in the first session of intermittent hemodialysis. Other than dialysis-associated imbalance syndrome, there is no evidence exploring the neurocognitive effects of the first hemodialysis session. Cognitive impairment is defined as a new deficit in two or more areas of cognitive function and its progression is associated with impaired kidney function. Most of the dysfunctions reported are in the domains of orientation, attention and executive functions. Therefore, the recognition of cognitive impairment can be done with tools such as the Minimental State Examination (MMSE) and the Montreal Cognitive Assessment (MOCA) test. Brain magnetic resonance imaging (MRI) can identify brain lesions such as 'silent' infarcts, microbleeds and white matter abnormalities in patients with CKD with and without RRT. Diffusion-weighted MRI before and after HD has shown brain edema in rats with dialysis-associated imbalance syndrome. In fact, there is evidence from brain MRI that before first HD session patients have interstitial cerebral edema, which worsens after the first HD treatment.

Because there is no clear evidence to support the choice of the modality in the first session and the prescription is still based on personal experiences and shared views. Therefore, we conducted a pilot study to determine the safest hemodialysis modality with the lowest risks and neurocognitive effects for patients with CKD and first HD treatment.
Standard treatment and participation in an activity without physical improvement as placebo condition (table soccer in groups of 4), but including cognitive training, 3 sessions (30 min. each) per week for 3 months and 2 sessions Cogpack per week for the last 6 weeks.
Researchers are increasingly using web-based technologies to deliver family-based, prevention programming. Few studies have examined the success of such approaches for families with low incomes. The purpose of this study was to describe the level of in-class and online engagement in a childhood obesity prevention program for parents with low incomes, to examine the demographic correlates of parent engagement, and to examine dosage effects on parental feeding outcomes as a function of online exposure. All participants attended in-class nutrition education classes (Eating Smart · Being Active) as part of the Expanded Food and Nutrition Education Program (EFNEP) in Colorado and Washington State (classes were offered in English and Spanish). Participants in this analysis were 168 parents from a larger cluster randomized controlled trial who had been randomly assigned to also receive a newly developed, mobile-based version of an efficacious, feeding-focused, childhood obesity prevention program. Results showed that despite high levels of in-person attendance (70%), participants only accessed 47% of the videos (online content). Older parents and parents of girls showed higher levels of in-person attendance; currently employed parents showed lower levels. Online engagement varied as a function of ethnicity and acculturation: non-Hispanic parents accessed the most videos, low-acculturated Hispanic parents accessed the second most, and highly acculturated Hispanic parents accessed the least. In contrast, low-acculturated Hispanic parents showed the highest in-person attendance. For all but one outcome, significant online program effects were found only for parents who accessed at least half of the videos. Implications for mobile-based, family-based prevention programs for parents with low incomes are considered.ClinicalTrials.gov Identifier: NCT03170700; Registration Date: March 08, 2017.
Phase B is an expansion study to evaluate the anti-tumor efficacy and safety of IPG1094 in patients with head and neck cancer (specific tumor types will depend on the results of Part A), with 12 subjects enrolled. A sparse sampling approach for PK with 3 to 4 time points on Day 1 and 3 to 4 time points on Day 28 of Cycle 1, and pre-dose on Day 1 of Cycle 2 and every other cycle thereafter (for example, C4D1, C6D1, C8D1) to allow for population PK and exposure-response (efficacy and safety endpoints) analyses.
VIVE mind will be a pragmatic, single-center, randomized controlled trial.

Users of PDHC with perceived distress (PSS-10), aged 18 years or over, will be recruited and randomly assigned into experimental and waiting list control group, in a 1:1 ratio. The recruitment of participants will be held in PDHC by health professional (e.g., family medicine doctors, nurses, nutritionists, psychologists, etc). After signed informed consent and baseline measures, experimental group will participate in body-mind sessions (yoga, qigong or pilates), oriented by certified instructors, during 6-months. Each participant should attend only one of the therapies, in order to guarantee a differentiated evaluation. In every session, it will be evaluated the participants' adherence and theirs perceived enjoyment and exertion. The other outcomes (primary and secondary) will be analyzed through a face-to-face contact, in three different moments: baseline (T0), post-intervention (at month 6, T1) and 6-month follow-up (at month 12, T2). The control group will not participate in any specific intervention, but will receive the body-mind intervention after the experimental period. An intention-to-treat and per protocol analysis will be performed to analyze intervention effectiveness and efficacy.
PURPOSE: To compare the relationship between macular ganglion cell layer (mGCL) thickness and 10-2 visual field (VF) sensitivity using different stimulus sizes in patients with temporal hemianopia from chiasmal compression.
METHODS: A cross-sectional study was conducted involving 30 eyes from 25 patients with temporal VF loss on 24-2 SITA standard automated perimetry due to previous chiasmal compression and 30 healthy eyes (23 controls). Optical coherence tomography (OCT) of the macular area and 10-2 VF testing using Goldmann stimulus size I (GI), II (GII), and III (GIII) were performed in the Octopus 900 perimeter. For the sake of analysis, mGCL thickness and VF data were segregated into four quadrants (two temporal and two nasal) and two halves (temporal and nasal) centered on the fovea, in order to evaluate separately both the severely affected nasal hemi-retina corresponding to the temporal VF sectors and the subclinically affected temporal hemi-retina corresponding to the nasal VF sectors. Data from patients and controls were compared using generalized estimated equations. The discrimination ability of GI, GII, and GIII was evaluated, as was the correlation between mGCL and 10-2 VF sensitivity using GI, GII, and GIII.
RESULTS: All mGCL parameters in the nasal and temporal halves of the retina were significantly reduced in patients compared to controls. 10-2 VF test sensitivity using GI, GII, and GIII was significantly lower in patients than in controls (p≤0.008) for all parameters, except the three nasal divisions when using GI (p = 0.41, 0.07 and 0.18) Significant correlations were found between temporal VF sectors (all stimulus sizes) and the corresponding nasal mGCL measurements, with similar discrimination ability. Significant correlations were also observed between all three nasal VF divisions and the corresponding temporal mGCL thickness when using stimulus sizes I and II, but not stimulus size III.
CONCLUSIONS: On 10-2 VF testing, GII outperformed GI and GIII with regard to discrimination ability and structure-function correlation with mGCL thickness in the subclinically affected nasal part of the VF in patients with chiasmal compression. Our findings suggest that the use of GII can enhance the diagnostic power of 10-2 VF testing in early cases of chiasmal compression, although further studies are necessary to support this conclusion.